A61K38/02

Prodrug for therapeutic applications

The disclosure provides for prodrugs of Fingolimod that were designed to specifically prevent phosphorylation during circulation, hence avoiding bradycardia and lymphopenia. The disclosure further provides for the use of the prodrugs in the treatment of cancer and multiple sclerosis in subjects in need of treatment thereof.

Prodrug for therapeutic applications

The disclosure provides for prodrugs of Fingolimod that were designed to specifically prevent phosphorylation during circulation, hence avoiding bradycardia and lymphopenia. The disclosure further provides for the use of the prodrugs in the treatment of cancer and multiple sclerosis in subjects in need of treatment thereof.

IMPROVING TEXTURE OF PROTEIN
20230210130 · 2023-07-06 ·

The present invention addresses the problem of providing a method for improving a texture of a protein. By allowing a protein deamidase to act on a substrate protein, a feeling of the protein on a tongue can be smoothened, and the texture thereof can be improved.

Amino acid compositions and methods of manufacturing the compositions
11547688 · 2023-01-10 ·

Nootropic compositions and methods of providing or using the same are provided herewith. Some preferred compositions include a combination of free amino acids and one or more peptides. Compositions may optionally include one or more of an anti-adherent, a B vitamin, shilajit, a sugar, a fatty acid, ashwaganda, ginseng, or rodiola, among other things.

Methods For Treating And/Or Preventing Hypersomnias
20220387546 · 2022-12-08 ·

Compounds, compositions, and methods for treating and/or preventing a neurological disease, a neuropsychiatric disease, a neurodegenerative disease, preferably narcolepsy and associated diseases or disorders.

Methods For Treating And/Or Preventing Hypersomnias
20220387546 · 2022-12-08 ·

Compounds, compositions, and methods for treating and/or preventing a neurological disease, a neuropsychiatric disease, a neurodegenerative disease, preferably narcolepsy and associated diseases or disorders.

Antibodies that bind human C6 and uses thereof
11590222 · 2023-02-28 · ·

Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.

Antibodies that bind human C6 and uses thereof
11590222 · 2023-02-28 · ·

Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.

USE OF TRANSFERRIN, TRANSFERRIN RECEPTOR AND ANTIBODY THEREOF IN PREPARATION OF ANTI-SARS-CoV-2 DRUG

The present disclosure provides use of transferrin, a transferrin receptor and an antibody thereof in the preparation of an anti-SARS-CoV-2 drug. Use of the transferrin, the transferrin receptor or the transferrin receptor antibody in the preparation of an anti-SARS-CoV-2 drug is provided. Both surface plasmon resonance (SPR) and immunofluorescence confirm that the SARS-CoV-2 binds to the transferrin receptor through SARS-CoV-2 spike protein; the transferrin and/or the transferrin receptor antibody competitively bind(s) to the transferrin receptor of the body, or the transferrin receptor competitively binds to a site of the SARS-CoV-2 to inhibit binding of the SARS-CoV-2 to the transferrin receptor of the body; thus, the opportunity that the SARS-CoV-2 infects cells is blocked, and the antiviral effect of the body is realized. Use of the transferrin, the transferrin receptor and the antibody thereof in the preparation of a SARS-CoV-2 spike protein-binding biological product is provided

USE OF TRANSFERRIN, TRANSFERRIN RECEPTOR AND ANTIBODY THEREOF IN PREPARATION OF ANTI-SARS-CoV-2 DRUG

The present disclosure provides use of transferrin, a transferrin receptor and an antibody thereof in the preparation of an anti-SARS-CoV-2 drug. Use of the transferrin, the transferrin receptor or the transferrin receptor antibody in the preparation of an anti-SARS-CoV-2 drug is provided. Both surface plasmon resonance (SPR) and immunofluorescence confirm that the SARS-CoV-2 binds to the transferrin receptor through SARS-CoV-2 spike protein; the transferrin and/or the transferrin receptor antibody competitively bind(s) to the transferrin receptor of the body, or the transferrin receptor competitively binds to a site of the SARS-CoV-2 to inhibit binding of the SARS-CoV-2 to the transferrin receptor of the body; thus, the opportunity that the SARS-CoV-2 infects cells is blocked, and the antiviral effect of the body is realized. Use of the transferrin, the transferrin receptor and the antibody thereof in the preparation of a SARS-CoV-2 spike protein-binding biological product is provided